Cenix and Debiopharm collaborate to identify oncology biomarkers

cebix debiopharm biomarkers oncology (Orin Zebest)

Cenix BioScience and Debiopharm have announced that they will collaborate to identify predictive biomarkers to aid development of preclinical oncology candidates. Cenix, a preclinical contract research provider and specialized in RNAi-, miRNA- and high content-driven pharmacology, will supply its expertise in high throughput screening and high content assays in cultured human cells to support Debiopharm's development of novel therapeutic drugs. You can read the press release here >

If you want to know more about early clinical development, including a talk on "Utilization of biomarkers in non-clinical development to guide early phase clinical development: Case studies with Nanobodies", you might be interested in attending Exploratory Clinical Development World Europe 2013, 4-6 June 2013.

TBP Exploratory foot banner

Leave a Reply

Your email address will not be published. Required fields are marked *